Latest KRAS Stories
Advancing Its Precision Cancer Monitoring Platform Using Liquid Biopsy to Improve the Standard of Cancer Care SAN DIEGO, March 12, 2015 /PRNewswire/ -- Trovagene, Inc.
DALLAS, March 2, 2015 /PRNewswire/ -- ReportsnReports.com adds Lonsurf and Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023 research report focuses on
THOUSAND OAKS, Calif., Feb.
Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA SAN DIEGO,
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO,
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.
MANHATTAN BEACH, Calif., Jan.